Adam Hardy PhD

In this paper we discuss how a coordinated launch across the whole of North America, as opposed to in US and Canada separately, can maximise patient access to novel products.

Our paper, “Successful Launches in Europe: Complex but Not Complicated,” discusses the challenges and opportunities associated with launching a pharmaceutical product in Europe. This paper emphasizes the need for pharmaceutical companies to adopt a comprehensive and strategic approach to launch planning, with a focus on understanding the diverse needs and regulations of different European markets. It also discusses the importance of building strong partnerships with key stakeholders, including… Show more

Our paper, “Successful Launches in Europe: Complex but Not Complicated,” discusses the challenges and opportunities associated with launching a pharmaceutical product in Europe. This paper emphasizes the need for pharmaceutical companies to adopt a comprehensive and strategic approach to launch planning, with a focus on understanding the diverse needs and regulations of different European markets. It also discusses the importance of building strong partnerships with key stakeholders, including healthcare professionals, patient advocacy groups, and payers. The article highlights the role of market access in the success of a launch, and provides insights on how companies can navigate the complex pricing and reimbursement systems in Europe. Finally, the paper discusses the potential of digital technologies to support launch planning and execution, including the use of data analytics to inform decision-making and improve patient outcomes. Show less

As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of its complexity, can be intimidating and may deter some companies from launching themselves. Companies may prefer to out-license or… Show more

As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of its complexity, can be intimidating and may deter some companies from launching themselves. Companies may prefer to out-license or sign agreements with distributors, which are the more traditional routes to market. However, these agreements result in less control for the manufacturer regarding all aspects of the launch strategy and decreased long-term company awareness and revenue stream.

The “holy grail” for launching in Europe must therefore combine the advantages of both self-launch and out-licensing/distributor relationships, resulting in maximal product revenue for the manufacturer over the long term. Show less

In this article, I highlight 3 strategies for clinical teams to think beyond gaining marketing approval as the end-goal of pharmaceutical R&D, and gain sight of the fact that the real “win” is to get the right product into as many patients’ hands, as quickly as possible.

White paper discussing how engaging experts in demonstrating a treatment's economic value early during clinical development can maximise revenue and market success, especially in Europe.

White paper describing how an innovative Contract Commercialization approach can yield quantifiable launch cost savings

This study is therefore the first to show that both P2Y(1) and P2Y(12) receptor activities are rapidly and reversibly modulated in human platelets, and it reveals that the underlying mechanism requires receptor trafficking as an essential part of this process.

This study reveals cross-desensitization between ADP and thromboxane receptor signaling in human platelets. Cross-desensitization is mediated by protein kinases, involving PKC-dependent and independent pathways, and indicates that alterations in the activation state of one receptor may have effects upon the sensitivity of the other receptor system.

This study therefore is the first to reveal distinct roles for PKC isoforms in the regulation of platelet P2Y receptor function and trafficking.

We conclude that P2Y12 plays a potentiatory role in ADP-induced shape change through regulation of the Rho kinase pathway, potentiating both myosin phosphorylation and actin polymerisation, and this forms part of an important signalling pathway additional to its well-established Gi-coupled pathways.

This study is the first to show that both P2Y(1) and P2Y(12) desensitize in human platelets, and it reveals ways in which their sensitivity to ADP may be differentially and independently altered.

Taken together, we present evidence for a complex signaling interplay between P2Y(1) and P2Y(12), where P2Y(12) is able to positively regulate P2Y(1) action and P2Y(1) negatively regulates this action of P2Y(12). It is likely that this interplay between receptors plays an important role in maintaining the delicate balance between platelet activation and inhibition during normal hemostasis.